奈达铂联合多西他赛治疗晚期宫颈癌的临床观察

Clinical Observation of Nedaplatin Combined with Docetaxel in the Treatment of Advanced Cervical Cancer

目的:探讨奈达铂联合多西他赛对晚期宫颈癌患者的临床疗效及安全性。方法:回顾性选取2014年4月-2016年4月于我院就诊的晚期宫颈癌患者53例,根据化疗方案分为观察组(31例)和对照组(22例)。对照组患者给予多西他赛注射液60 mg/m^2,ivgtt,qw;观察组患者在对照组基础上给予注射用奈达铂35 mg/m^2+0.9%氯化钠注射液稀释至500 m L,ivgtt(≥60 min),qw。两组患者均以21 d为1个化疗周期,行2个周期化疗。两组患者治疗结束2周后评价临床疗效,检测治疗前及治疗结束2周后增殖细胞核抗原(PCNA)积分,并记录不良反应发生情况。结果:观察组患者的总有效率(77.42%)明显高于对照组(63.64%),差异有统计学意义(P<0.05)。治疗前,两组患者PCNA积分比较,差异无统计学意义(P>0.05);治疗后,两组患者PCNA积分均明显降低,且观察组明显低于对照组,差异有统计学意义(P<0.05)。两组患者各项不良反应均集中在I度,且不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:奈达铂联合多西他赛可明显提高晚期宫颈癌患者的临床疗效,与多西他赛单独使用相比,并不会增加不良反应的发生。

OBJECTIVE： To explore the clinical efficacy and safety of nedaplatin combined with docetaxel in the treatment of advanced cervical cancer. METHODS： A total of 53 patients with advanced cervical cancer selected from our hospital during Apr. 2014-Apr. 2016 were divided into observation group （31 cases） and control group （22 cases） according to chemotherapy plan. Control group was given Docetaxel injection 60 mg/m2, ivgtt,qw. Observation group was additionally given Nedaplatin for injection 35 mg/m2＋0.9% Sodium chloride injection diluted into 500 mL, ivgtt （≥60 min）, qw. A chemotherapy cycle lased for 21 d, and both groups received 2 cycles of chemotherapy. Clinical efficacies of 2 groups were evaluated 2 weeks after treatment, and the level of PCNA integal was detected before and 2 weeks after treatment. The occurrence of ADR was recorded. RESULTS： The total response rate of observation group （77.42%） was significantly higher than that of control group （63.64%）, with statistical significance （P〈0.05）. Before treatment, there was no statistical significance in PCNA integval between 2 groups （P〉0.05）. After treatment, PCNA integval of 2 groups were decreased significantly, and the observation group was significantly lower than the control group, with statistical significance （P〈0.05）. ADR were concentrated in grade I, and there was no statistical significance in the incidence of ADR between 2 groups （P〉0.05）. CONCLUSIONS： Docetaxel combined with nedaplatin can significantly improve the clinical efficacy of patients with advanced cervical cancer, and does not increase the adverse reactions compared to docetaxel alone.